Corporate Social Responsibility | Business Wire | PR NewsWire | Marketwire | Realwire | ACN/JCN newswire | 247pressrelease | PRWeb

SuperGen Presentations at AACR-NCI-EORTC

DUBLIN, Calif. - 
      SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the 
      discovery and development of novel cancer therapies, today announced the 
      acceptance of seven abstracts for poster presentations on November 16, 
      17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Target
Posted : Mon, 09 Nov 2009 11:02:00 GMT
Author : SuperGen, Inc.
Category : Press Release
News Alerts by Email ( click here )
Press Release News | Home
DUBLIN, Calif. - (Business Wire) SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.

SuperGen’s presentations will review clinical and non-clinical advances in the following compounds: MP-470, SGI-1776, SGI-110, SGI-1252, as well as two presentations on the Etk program. The posters will be made available for viewing on the company’s website www.supergen.com following the respective presentations.

MP-470: The tyrosine kinase inhibitor MP470 inhibits RAD51-mediated homologous recombination and increases tumor cell radio- and chemosensitivity

Abstract A122, Monday Nov 16, 12:30 – 2:30 pm EST
 

SGI-110: In vivo activity of SGI-110, a novel hypomethylating agent for treatment in hematology and solid malignancies

Abstract A190, Monday Nov 16, 12:30 – 2:30 pm EST
 

MP-470: A self-emulsifying lipid suspension formulation enhances oral bioavailability of MP-470 in a randomized two-way crossover study in healthy male subjects

Abstract B209, Tuesday Nov 17, 12:30 – 2:30 pm EST
 

SGI-1776: The novel PIM kinase inhibitor SGI-1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma

Abstract B272, Tuesday Nov 17, 12:30 – 2:30 pm EST

 

ETK/BMX: Mechanistic, functional and in vivo efficacy of inhibiting ETK/BMX in cancer models

Abstract B263, Tuesday Nov 17, 12:30 – 2:30 pm EST
 

SGI-1252: In vivo activity of SGI-1252, a potent, small-molecule dual inhibitor of JAK2 and ALK2

Abstract C206, Wednesday Nov 18, 12:30 – 2:30 pm EST
 

ETK: Development of potent, small-molecule inhibitors of ETK

Abstract C199 Wednesday Nov 18, 12:30 – 2:30 pm EST

About SuperGen

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit http://www.supergen.com.

SuperGen, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Business Development
tenns@supergen.com
Susanna Chau, 925-560-2845
Manager
Investor Relations
schau@supergen.com


Copyright © 2008 Business Wire. All rights reserved.
Share/Save/Bookmark



Related News

Ontario's Green Builder Abcott Construction are proud of our green LEED Partnership with Butler Manufacturing
Ontario's Green Builder Abcott Construction are proud of our green LEED Partnership with Butler Manufacturing

Toronto Revitalization Infrastructure Project - LEEDing the way in Regent Park Demolition
We are very proud of our Green Philosophy at REC Demolition Restoration Environmental, we had an impressive acheivement of reaching 94.7% LEED success in three R's: Reduce, Recycle, Re-use a truly LEEDing the Way in Toronto a contractors success!

Fandango Sells a Record-Breaking 18% of 'New Moon' Opening Weekend Box Office
LOS ANGELES, Nov. 22 /PRNewswire/ -- Fandango, the nation's leading movie ticketing destination, announced today that it sold nearly 18% of all tickets for "The Twilight Saga: New Moon", which took in a projected domestic weekend box office of $140.7 million*. (Pho...

Jennifer Jo Cobb Set to Drive the #84 MC2 Energy Drink Dodge at the Ford 300 NASCAR Nationwide Series Race at Homestead-Miami Speedway
LAS VEGAS, NV and MOORESVILLE, NC -- 11/22/09 -- Beverage Plus Holdings Corporation (PINKSHEETS: CLNP) and FCBBI AG (FRANKFURT: 3FC.de) and Mike Harmon Racing announced today that Jennifer Jo Cobb will be behind the wheel on the 1.5 mile Speedway i..

Klim USA Selects PLM, Sourcing from Centric Software
Focus on speeding sample development, on-time product design and delivery/I/P PCampbell, Calif. (PRWEB) August 26, 2009 -- Klim USA, a rapidly growing maker of advanced technical riding gear for today's aggressive off-road dirt bike and snowmobile rider, has become the most recent appar...

Centric Software Hosts Customer Advisory Board Meeting
Focus on issues facing customers in fast-moving consumer goods, fashion industries/I/P PCampbell, CA (PRWEB) September 30, 2009 -- Centric Software hosted a fashion and consumer goods Customer Advisory Board meeting last week in New York, New York. The event included executives...

Daniel P. Quinn, Author of 'organized labor' (AuthorHouse), and Exits & Entrances, available for Interviews in 2009/10..
Daniel P Quinn's organized labor is a panoramic survey of labor history in poetic verse with historic photographs. From New York's Landmark Tavern in the 1890's to the 1913 strike at the Botto House Museum, Haledon, NJ. Mr. Quinn shapes a vision both old and new of his family history and tha...

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark
 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.